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INTRODUCTION
In terms of metastasis, the ovaries are the most commonly
involved organ, in the female genital tract. The appearance
of ovaries containing metastases vary greatly, and the prima-
ry ovarian tumors are a heterogeneous groups of neoplasms,
with different histopathologic features and variable clinical
behaviors. It is known that findings suggestive of metastasis
are bilaterality, the presence of multiple discrete nodules either
within the substance of the ovary or on its surface, and vascu-
lar invasion (1). However, a significant proportion of metastatic
carcinomas to the ovary show histologic features reminiscent
of primary ovarian carcinoma, and in some instances, histo-
logic features show considerable overlap (2). Thus it may be
difficult to differentiate between these two entities by using
clinical and histologic backgrounds, but the differential diag-
nosis is of paramount importance for therapeutic and prog-
nostic purposes. Immunohistochemistry may play a funda-
mental role in this circumstance. Currently available immuno-
histochemical markers, such as cytokeratin (CK)7, CK20,
carcinoembryonic antigen (CEA), human alveolar macrophage-
56 (HAM-56), mucin marker (MUC)2, and MUC5AC, are
of limited sensitivity and specificity, even though in many
settings, they allow the site of origin of a metastatic lesion
to be identified (3-7). For this reason, continued interest is
shown in the development of new and more specific mark-
ers for intestinal differentiation. CDX-2, a homeobox gene
encoding an intestine-specific transcription factor, appears to
be such a marker (8). CDX-2 plays a role in directing early
processes in intestinal cell morphogenesis and in the main-
tenance of the differentiated phenotype by supporting the
transcription of differentiated gene products. Moreover, recent
studies have shown that CDX-2 has a specific expression in
normal colonic epithelium and in most colorectal adenocar-
cinomas, and thus CDX-2 immunohistochemistry has been
suggested to be of use for establishing the gastrointestinal
origins of metastatic tumors (9), although the expression of
CDX-2 is not entirely exclusive to intestinal carcinomas (10).
In this study, we examined CDX-2 expression in all subtypes
of primary ovarian adenocarcinoma and in metastatic adeno-
carcinoma to the ovary, including metastasis of gastric and
appendiceal origin. We also evaluated the usefulness of an
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The Usefulness of CDX-2 for Differentiating Primary and Metastatic
Ovarian Carcinoma: An Immunohistochemical Study Using a Tissue
Microarray
Distinguishing primary ovarian carcinoma from metastatic carcinoma to the ovary
is often difficult by histologic examination alone. Recently an immunohistochemi-
cal marker CDX-2 was found to be of considerable diagnostic value in establishing
the gastrointestinal origin of metastatic tumors. The aim of this study was to deter-
mine whether CDX-2 can distinguish between these malignancies. Paraffin-embed-
ded tissue sections from 57 primary ovarian tumors and 40 metastatic tumors to
the ovary were immunostained for CDX-2, and results were compared to the ancil-
lary immunohistochemical results for CK7/CK20, CEA, CA125, and her-2/neu.
CDX-2 immunoreactivity was observed in most of metastatic carcinomas with colo-
rectal (91%) and appendiceal (100%) origin, however CDX-2 was negative in all
primary ovarian carcinomas, except for the mucinous subtype. Almost all primary
ovarian carcinomas including the mucinous subtype showed diffuse and strong
immunoexpression for CK7. CEA and CA125 were mainly found in metastatic and
primary ovarian carcinoma, respectively. Her-2/neu overexpression was only noted
in a small proportion of primary and metastatic ovarian carcinomas. These results
suggest that CDX-2 is very useful immunohistochemical marker for distinguishing
metastatic colorectal carcinoma to the ovary from primary ovarian carcinoma, includ-
ing the mucinous subtype. Furthermore, combination with CDX-2 and CK7 strength-
en the differential diagnosis between these tumors.
Key Words : Cdx-2-3 protein; Ovarian Neoplasms; Adenocarcinoma; Neoplasm Metastasis; Immunohisto-
chemistry
Received : 25 November 2004
Accepted : 3 February 2005644 M.J. Kim 
immunohistochemical panel consisting of CK7, CK20, CEA,
CA125, and her-2/neu, for distinghuising between these two
groups of lesions. The aim of this study was to investigate
the possible immunohistochemical use of CDX-2 in this
context, and to identify a combination of immunohistochem-
ical markers that can be used for the differential diagnosis of
primary ovarian carcinoma and metastatic carcinoma.
MATERIALS AND METHODS
Materials
Primary and metastatic ovarian carcinoma samples were
obtained from the Department of Pathology of Yeungnam
University Hospital. The series included 26 cases of serous
adenocarcinoma, 18 cases of mucinous adenocarcinoma, 6
cases of endometrioid adenocarcinoma, 7 cases of clear cell
adenocarcinoma, and 40 cases of metastatic adenocarcinoma
of different origin including 18 stomach, 11 colorectum, 7
appendix, 1 breast, 1 lung, 1 pancreas, and 1 kidney. Appen-
diceal metastases were low-grade mucinous epithelial tumors.
Specimens were obtained by surgical resection in all cases. All
metastatic carcinomas had recognized original sites proven by
histologic examination of the primary lesion. The distinction
between primary and metastatic mucinous adenocarcinomas
was sometimes based on well-defined clinicopathologic cri-
teria (11).
Tissue microarray
For immunohistochemical analysis a tissue microarray (TMA)
technique was used, which allowed the  staining of a large
numbers of specimens on one slide. TMAs were prepared
manually using a dermal punch biopsy needle, reconstructed
by our laboratory. Details of the technique have been described
previously (12). To account for cancer tissue heterogeneity, 2
to 3 cylindrical core biopsies, 2.0 mm in diameter, were care-
fully taken from different sites of each tumor to include all
histological patterns, and then arrayed in a recipient paraf-
fin TMA block. 
Immunohistochemistry
Sections (4 m) were mounted on poly-L-lysine-coated slides
for immunohistochemical analysis using a labeled strepta-
vidin-biotin-peroxidase method (DAKO, Carpinteria, CA,
U.S.A.). Primary antibodies to CDX-2, CK7, CK20, CEA,
CA125, and her-2/neu were using in the study (Table 1).
Briefly, TMA sections were deparaffinized, rehydrated in
graded alcohols and treated for 5 min with 1% H2O2. Sec-
tions for CA125, and her-2/neu immunohistochemistry were
subjected to microwave antigen retrieval and then incubat-
ed for 30 min. After rinsing sections in PBS and incubating
them with normal goat serum for 6 min, all pre-diluted pri-
mary antibodies were applied for 60 min at room tempera-
ture. The sections were then allowed to react with peroxidase
conjugated streptavidin for 45 min. Color development was
performed using diaminobenzidine, and then counterstained
with hematoxylin. Colorectal mucosa and adenocarcinomas
were used as positive controls for CDX-2. Immunoreactiviy
was considered positive if more than 10% of the neoplastic
cells showed nuclear (CDX-2, her-2/neu) or cytoplasmic (CK7/
20, CEA, CA125) immunoreactivity. Tumors were scored
in a semiquantitative method according to the following
scheme: 0 (less than 10% of tumor cells); 1+ (positive signal
of any intensity in 11-40% of tumor cells); 2+ (greater than
41% of tumor cells). 
Statistical analysis
Immunohistochemical data were expressed as total num-
bers (or percentages) of cases showing  positive staining. The
relations between primary ovarian tumors and metastatic
tumors, with or without immunoreactivity were evaluated
using the chi-square test. Statistical significance was for p
values <0.05. The specificity and sensitivity of the investi-
gated markers for primary and metastatic ovarian carcinomas
were calculated as follows: specificity=true negatives/(true
negatives+false positives); and sensitivity=true positives/
(true positives+false negatives).
RESULTS
The results of the immunohistochemical studies are sum-
marized in Table 2. 
CDX-2-immunohistochemical findings 
CDX-2 immunoreactivity was visualized as a fine granular
to diffuse staining pattern confined to nuclei. Control speci-
mens showed that most nuclei of the normal intestinal epithe-
lium and in colorectal adenocarcinoma cells were strongly
reactive for CDX-2. Overall, CDX-2 immunoreactivity was
detected in 10 of 57 (18%) primary ovarian carcinomas, and
25 of 40 (63%) metastatic ovarian carcinomas, with signifi-
Antibody Dilution Pretreatment Source
CDX-2 1:120 pH8.0 EDTA buffer BioGenex, San Ramon, U.S.A.
CK7 1:30 Enzyme DAKO, Glostrup, Denmark
CK20 1:30 Enzyme DAKO, Glostrup, Denmark
CEA 1:30 10 mM citrate buffer DAKO, Carpinteria, U.S.A.
CA125 1:20 10 mM citrate buffer, DAKO, Carpinteria, U.S.A.
Microwave
Her-2/neu 1:50 10 mM citrate buffer, ZYMED, San Francisco, U.S.A.
Microwave
Table 1. Antibodies used in this studycance (p<0.0001). In primary ovarian carcinoma, CDX-2
immunostaining was observed in 10 of 18 (56%) cases of
mucinous adenocarcinoma only, and all serous, endometri-
oid, and clear cell adenocarcinomas of the ovary were CDX-
2 negative. In metastases, CDX-2 expression was identified
in 7 of 7 (100%) of appendiceal origin, 10 of 11 (91%) of
colorectal origin, and in 8 of 18 (44%) of gastric origin. All
cases of colorectal and appendiceal origin were strongly and
diffusely positive (2+) for CDX-2, which compared with
weak, focal positivity (1+) in other immunoreactive tumors
(Table 3, Fig. 1). CDX-2 appears to be a highly sensitive and
specific immunologic marker of intestinal differentiation. No
CDX-2 immunostaining was identified in 4 cases of metastat-
ic adenocarcinomas from lung, pancreas, breast, or kidney. 
CK7- and CK20-immunohistochemical findings 
CK7 and CK20 immunoreactivities were observed in 55
of 57 (97%) and 20 of 57 (35%) primary ovarian carcinomas,
respectively, and in 23 of 40 (58%) and 35 of 40 (88%) meta-
static carcinomas. CK7 was expressed in all serous subtypes
and in 17 of 18 (94%) of mucinous subtype, whereas CK20
expression was observed in all cases (100%) of colorectal and
appendiceal carcinoma, and in 16 of 18 (89%) cases of gas-
tric carcinoma. A tendency was observed for more diffuse
CK7 staining in primary ovarian carcinoma rather than in
metastatic carcinoma and conversely, the expression of CK20
was more likely to be diffuse in metastases than in primaries
(Table 3, Fig. 2). The immunoprofiles of CK7 and CK20
were significantly different in these two groups (p<0.0001). 
CEA-immunohistochemical findings 
CEA expression revealed a significant differences between
primary versus metastatic tumors in the ovary (p<0.0001). CEA
staining was noted in 11 of 18 (61%) of ovarian mucinous
carcinomas, and in 10 of 11 (91%) metastatic carcinomas of
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CDX-2 CK7 CK20 CEA CA125 Her2/neu
Tumor type
No. of positive/total cases (%)
Primary carcinoma
Serous 0/26 26/26 (100) 6/26 (23) 0/26 26/26 (100) 0/26
Mucinous 10/18 (56) 17/18 (94) 12/18 (67) 11/18 (61) 4/18 (22) 3/18 (17)
Clear cell 0/7 7/7 (100) 0/7 0/7 6/7 (86) 2/7 (29)
Endometrioid 0/6 5/6 (83) 2/6 (33) 1/6 (17) 1/6 (17) 0/6
Metastatic carcinoma
Stomach 8/18 (44) 14/18 (78) 16/18 (89) 12/18 (67) 0/18 (0) 2/18 (11)
Colorectum 10/11 (91) 6/11 (55) 11/11 (100) 10/11 (91) 1/11 (9) 0/11
Appendix 7/7 (100) 0/7 7/7 (100) 7/7 (100) 0/7 0/7
Lung 0/1 1/1 (100) 0/1 1/1 (100) 0/1 0/1
Pancreas 0/1 1/1 (100) 1/1 (100) 1/1 (100) 0/1 0/1
Breast 0/1 1/1 (100) 0/1 0/1 1/1 (100) 0/1
Kidney 0/1 0/1 0/1 0/1 0/1 0/1
Table 2. Immunohistochemical results in evaluated ovarian tumors
CK20 CK7 CDX-2 Tumor
type 0 1+ (%) 2+ (%) 0 1+ (%) 2+ (%) 0 1+ (%) 2+ (%)
Serous 26 0 ( 0 ( 00   ( 26 ( 20 6 (23) 0 (
Mucinous 8 6 (30) 4 (22) 1 1 (6) 16 (89) 6 4 (22) 8 (44)
Clear cell 7 0 ( 0 ( 00   ( 7 (100) 7 0 ( 0 (
Endo- 6 0 ( 0 ( 10   ( 5 (83) 4 2 (33) 0 (
metrioid
Stomach 10 6 (30) 2 (11) 4 2 (11) 12 (67) 2 8 (44) 8 (44)
Colon 1 1 (9) 9 (82) 5 6 (55) 0 ( 0 4 (36) 7 (64)
Appendix 0 0 ( 7 (100) 7 0 ( 0 ( 00   ( 7 (100)
Table 3. The expression of CDX-2, CK7, CK20 in primary and
metastatic ovarian tumors according to the extent of positivity
Fig. 1. Representative sections of diffuse CDX-2 immunoreactivity
in primary ovarian mucinous adenocarcinoma (A) and in metastat-
ic carcinoma from colorectum (B), stomach (C) and appendix (D)
(×40).
A B
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colorectal origin and in all of appendiceal origin. CEA immu-
noreactivity was prevalent in gastrointestinal tumors (Table 4).
CA125-immunohistochemical findings 
CA125 was expressed in 35 of 57 (61%) and in 2 of 40
(5%) primary and metastatic tumors, respectively, with sig-
nificance (p<0.0001). In particular, the serous subtype showed
100% reactivity for CA125 (Fig. 3), whereas only 4 of 18
(22%) of the mucinous subtype showed CA125 immunos-
taining . 
Her-2/neu-immunohistochemical findings 
No significant difference was observed between the prima-
ry and metastatic groups with respect to her-2/neu expres-
sion. Her-2/neu immunoreactivity was observed in 2 of 7
(29%) primary clear cell subtype, 3 of 18 (17%) mucinous
subtype, and in 2 of 18 (11%) metastatic gastric carcinomas
(Fig. 3).
DISCUSSION 
Metastatic carcinomas account for approximately 15% of
malignant neoplasms involving the ovary. The most common
primary sites are the stomach, large bowel, appendix, breast,
uterus, lung and skin. In this study, metastases of gastric ori-
gin was most frequent, probably due to the exceptional preva-
lence of gastric carcinoma in Korea. In contrast, metastatic
carcinoma from the breast showed a very low incidence, even
though breast carcinoma is now the most common malig-
nancy in Korean women. Moreover 80% of ovarian metas-
tases from extragenital sites are derived from gastrointestinal
tract carcinomas and these commonly mimic primary neo-
plasms (2). The problems encountered in attempting to dif-
ferentiate between primary ovarian carcinoma and ovarian
metastases from colonic carcinoma on a histological basis alone
have prompted an intensive search for immunohistochemical
markers that could aid  this differential diagnosis. A grow-
ing body of literature (13-16) has recently dealt with CDX-
2 immunoreactivity in benign and malignant lesions of the
gastrointestinal tract, such as intestinal metaplasia of the stom-
ach, intestinal-type gastric cancer, and primary and metastatic
Fig. 2. Almost all primary ovarian mucinous carcinomas are dif-
fusely positive for CK7 (A), and variably positive for CK20, often
showing patchy rather than diffuse staining (B). Conversely, meta-




Fig. 3. Diffuse strong cytoplasmic staining for CA125 is observed
in ovarian serous carcinoma (A). Her-2/neu expression is evident
in a small group of the ovarian mucinous (B) and clear cell carci-
nomas (C) and unexpectidly in metastatic carcinomas from the
stomach (D) (×40). 
A B
C D
Her-2/neu CA125 CEA Tumor
type 0 1+ 2+ 0 1+ 2+ 0 1+ 2+
Serous 26 0 ( 0 ( 00   ( 26 (100) 26 0 ( 0 (
Mucinous 7 8 (44) 3 (17) 14 2 (11) 2 (11) 15 0 ( 3 (17)
Clear cell 7 0 ( 0 ( 1 1 (14) 5 (45) 5 2 (29) 0 (
Endo- 5 0 ( 1 (17) 5 0 ( 1 (17) 6 0 ( 0 (
metrioid
Stomach 6 4 (22) 8 (44) 18 0 ( 0 ( 16 0 ( 2 (11)
Colon 1 2 (18) 8 (73) 10 1 (9) 0 ( 11 0 ( 0 (
Appendix 0 0 ( 7 (100) 7 0 ( 0 ( 70   ( 0 (
Table 4. The expression of CEA, CA125, Her-2/neu in primary
and metastatic ovarian tumors according to the extent of posi-
tivityCDX-2 for Differentiating Primary and Metastatic Ovarian Carcinoma 647
intestinal adenocarcinomas. Our analysis concurs with other
studies with respect to CDX-2 immunostaining results (10,
17-19). We found a high prevalence of CDX-2 immunore-
activity, which showed a more homogeneous, stronger stain-
ing patterns, in metastatic carcinomas from colon and appen-
dix. However CDX-2, either focal or diffuse, was also express-
ed in more than 50% of primary mucinous carcinomas. CDX-
2 was not expressed by non-mucinous subtypes, which con-
trasts to the 20% and 10.5% immunoreactivity for CDX-2
observed in endometrioid carcinomas as reported by Logani
et al. (18) and Kaimaktchiev et al. (20). In addition, signifi-
cant CDX-2 expression in ovarian mucinous adenocarcino-
ma has been demonstrated by other series, in which it was
observed in from 10.5% to 100% of cases (14, 17-19). The
result of the present study might be of great diagnostic value
with respect to the differentiation of primary non-mucinous
adenocarcinomas and metastatic colorectal carcinomas, but
as in many settings, this marker can not distinguish primary
mucinous carcinoma from metastatic mucinous carcinoma to
the ovary. Fraggetta et al. (19) suggested that CDX-2 should
be considered as a cell-type related antigen rather than as an
organ specific marker. Extra-intestinal immunoreactivity for
CDX-2 has been rarely reported in urinary bladder adeno-
carcinoma, thyroid papillary carcinoma, carcinoid tumor (10),
lung adenocarcinomas (21), cervical adenocarcinoma (22), and
sinonasal adenocarcinoma (23) as well as in ovarian mucinous
lesions (10, 19), although CDX-2 immunoreactivity showed,
by far, the highest prevalence in carcinomas of intestinal ori-
gin. This unexpected expression of CDX-2 needs further in-
vestigation. 
The combined expression profiles of CK7 and CK20, the
most widely used immunohistochemical markers, is already
an established parameter in the differential diagnosis of ovar-
ian primaries from metastatic carcinoma to the ovary. The
coordinate expression of these markers has been very useful
for distinguishing between ovarian carcinomas (usually CK7+/
CK20-) and colorectal carcinomas (usually CK7-/CK20+)
(3, 4). However, occasionally colorectal carcinoma shows
CK7 expression and conversely, CK20 expression has been
observed in primary ovarian carcinoma (24, 25), and thus
this immunohistochemical staining is not helpful for differen-
tial diagnoses. The data presented in this study and in other
reports (3, 4) indicate that almost all primary ovarian carci-
nomas are diffusely positive for CK7 and variably positive
for CK20, and conversely, that almost all metastatic colorec-
tal carcinomas are diffusely positive for CK20 and variably
positive for CK7. Therefore, considerations of staining dis-
tributions of CK7 and CK20 within a tumor  still have a
great value in terms of identifying the primary site of a meta-
static lesion. In particular, the markers used in this study
have diagnostic utility in terms of excluding metastatic col-
orectal adenocarcinomas from ovarian mucinous and endometri-
oid adenocarcinomas, which most commonly mimic intesti-
nal adenocarcinoma.
CEA expression appears to offer another route of approach-
ing the differential diagnosis of primary and metastatic lesions.
CEA is overexpressed in a variety of human tumors, includ-
ing cervical, colorectal, gastric, pancreatic, ovarian, breast,
and non-small cell lung carcinomas (27). In our series, CEA
was mainly expressed in  carcinomas of colorectal and appen-
diceal origin, and in ovarian carcinoma, especially of the muci-
nous subtype. This study therefore indicates that CEA is not
suitable for differentiating ovarian mucinous carcinoma from
metastatic colorectal carcinoma, as shown by the data pre-
sented in CDX-2 (Table 2). However CDX-2 was more supe-
rior to CEA because CEA was less specific to establish intesti-
nal differentiation in that CEA immunoreactivity was more
prevalent in primary mucinous carcinoma, compared to CDX-
2, and also overexpressed in metastatic pulmonary and pan-
creatic carcinoma. In this situation, a combined panel of CEA
and other known markers, such as CK7 and CK20, is nec-
essary to distinguish  primary and metastatic mucinous car-
cinomas. CA125 is undoubtedly associated with primary
ovarian carcinoma (28). CA125 immunoreactivity was found
to be a good marker for identifying serous and clear cell sub-
types, regardless of differentiation. Thus CA125 immunore-
activity could be useful for the subtyping of ovarian carcino-
ma. However it is not helpful at distinguishing ovarian muci-
nous carcinomas from metastatic mucinous carcinomas, even
though the latter showed a tendency of focal staining. The
overexpression of her-2/neu is observed in 25-30% of breast
carcinomas and this is associated with a poor prognosis. Rela-
tively little is known concerning the relationship between
her-2/neu status and ovarian carcinoma (29). In a few instances
her-2/neu immunoreactivity was detected in ovarian clear
cell carcinomas (29, 30). This marker was demonstrated in
29% of clear cell carcinoma and 17% of mucinous carcino-
ma, according to this study, and interestingly her-2/neu im-
munoreactivity was found to be present in 2 cases of metastat-
ic gastric carcinoma. However at present, the literature con-
tains no data on her-2/neu expression in intestinal carcinoma.
Taken together the results available to date suggest that
the differential diagnosis of primary and metastatic mucinous
carcinoma pose greatest difficulty because both tumors can
share an immunophenotype and gross and microscopic fea-
tures. CDX-2 immunoreactivity may help in their differen-
tial diagnosis, but this marker is not entirely restricted to cells
showing the morphological appearance of intestinal type epithe-
lium, and is rarely aberrantly expressed in other tumor cells.
Therefore, CDX-2 immunoreactivity should be supported by
an immunohistochemical panel of well-known markers. We
conclude that CDX-2 is a highly sensitive marker for colonic
carcinoma metastatic to the ovary, and that CDX-2 and CK7
are the best combination of immunohistochemical marker
for differentiating metastatic carcinoma to the ovary from
primary ovarian carcinoma including the mucinous subtype.REFERENCES
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